NCT02522052

Brief Summary

Rheumatoid arthritis (RA) is a chronic disease that affects \~1% of the population. A large proportion of patients with established disease have persistent high disease activity in spite of existing effective pharmacological treatment. Improved treatment is thus urgently needed, including alternative treatments in addition to optimal pharmacological therapy. The main purpose of this study is to investigate if a high intake of blue mussel (Mytilus Edulis) could decrease inflammation and disease activity in patients with established RA. A secondary goal is to identify novel biomarkers for blue mussel intake and metabolic responses to this diet, using a metabolomics approach with high sensitivity and specificity. A third goal is to look at genetic polymorphisms in relation to long chain polyunsaturated fatty acids (LCPUFA) and inflammatory markers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
23

participants targeted

Target at below P25 for not_applicable rheumatoid-arthritis

Timeline
Completed

Started Aug 2015

Shorter than P25 for not_applicable rheumatoid-arthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 29, 2015

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

August 13, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
Last Updated

November 19, 2024

Status Verified

November 1, 2024

Enrollment Period

9 months

First QC Date

April 29, 2015

Last Update Submit

November 15, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • difference between disease activity score 28 (DAS28) after the diets

    Measured clinically

    after 11 week intervention

Secondary Outcomes (3)

  • difference in inflammatory markers/cytokines (IL-1beta, IL-6, Tumor Necrosis Factor-alfa, IL-10) after the diets

    after 11 week intervention

  • Difference in Quality of life and health by SF36, EQ5D och HAQ after the diets

    after 11 week intervention

  • Differences and changes in metabolites after the two diets

    after 11 week intervention

Other Outcomes (5)

  • Difference in plasma and RBC fatty acids after the diets and changes during the diets

    after 11 week intervention

  • Differences between blood lipids (TAG, HDL, LDL) after the diets

    after 11 week intervention

  • Differences in Hb after the diets

    after 11 week intervention

  • +2 more other outcomes

Study Arms (2)

Blue mussel diet

EXPERIMENTAL

5 meals a week including blue mussels

Other: Blue mussel diet

Meat/control diet

ACTIVE COMPARATOR

5 meals a week including meat

Other: Meat/Control diet

Interventions

5 meals a week containing blue mussels

Blue mussel diet

5 meals a week containing meat

Meat/control diet

Eligibility Criteria

Age25 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • BMI 18-40 kg/m2,
  • disease duration \>2 years,
  • DAS28 \>3.0

You may not qualify if:

  • other Life-threatening disease,
  • pregnant,
  • lactating,
  • food intolerant or allergic to food included in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sahlgrenska University Hospital

Gothenburg, Not in US/Canada, 405 30, Sweden

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Helen M Lindqvist, PhD

    Göteborg University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 29, 2015

First Posted

August 13, 2015

Study Start

August 1, 2015

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

November 19, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Not approved by the Ethical Review board

Locations